Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, ProKidney Corp’s stock clocked out at $0.75, up 3.96% from its previous closing price of $0.72. In other words, the price has increased by $3.96 from its previous closing price. On the day, 0.61 million shares were traded.
Ratios:
To gain a deeper understanding of PROK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.93 and its Current Ratio is at 10.93.
On September 10, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 22 ’25 when Control Empresarial de Capital bought 387,393 shares for $0.71 per share. The transaction valued at 276,366 led to the insider holds 73,842,723 shares of the business.
Control Empresarial de Capital bought 25,000 shares of PROK for $18,690 on Apr 17 ’25. The Add’l Rep. Persons-see Ex.99-1 now owns 73,455,330 shares after completing the transaction at $0.75 per share. On Apr 16 ’25, another insider, Control Empresarial de Capital, who serves as the Add’l Rep. Persons-see Ex.99-1 of the company, bought 100,000 shares for $0.75 each. As a result, the insider paid 74,820 and bolstered with 73,430,330 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1214.44.
Stock Price History:
Over the past 52 weeks, PROK has reached a high of $4.44, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -13.09%, while the 200-Day Moving Average is calculated to be -54.12%.
Shares Statistics:
A total of 128.05M shares are outstanding, with a floating share count of 91.19M. Insiders hold about 29.60% of the company’s shares, while institutions hold 41.44% stake in the company.
Earnings Estimates
The performance of ProKidney Corp (PROK) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.18 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.68 and -$0.68 for the fiscal current year, implying an average EPS of -$0.68. EPS for the following year is -$0.59, with 5.0 analysts recommending between -$0.46 and -$0.79.
